Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43

P Bourassa1,2, C Tremblay2, J A Schneider3

  • 1Faculté de pharmacie, Université Laval, Québec, QC, Canada.

Abstract

Insights

Brain mural cell (BMC) loss is linked to Alzheimer's Disease (AD) pathology. Reduced BMC markers correlate with cognitive decline and TDP-43 aggregation, suggesting cerebrovascular defects contribute to dementia.

Area of Science:

  • Neuroscience
  • Cerebrovascular Biology
  • Alzheimer's Disease Research

Background:

  • Brain mural cells (BMCs), comprising smooth muscle cells and pericytes, are crucial for cerebrovascular functions.
  • Dysfunction of BMCs is implicated in the pathophysiology of Alzheimer's Disease (AD).

Purpose of the Study:

  • To investigate the association between BMC markers and AD pathology.
  • To determine the relationship between BMC levels, cognitive function, and key AD biomarkers.

Main Methods:

  • Western immunoblotting was used to assess BMC markers (α-SMA, PDGFRβ, CD13) in parietal cortex microvessels from elderly participants.
  • Correlations were analyzed between BMC marker levels, cognitive scores, vascular amyloid-beta 40 (Aβ40), and phosphorylated transactive response DNA binding protein 43 (TDP-43).

Main Results:

  • Individuals with AD showed reduced vascular levels of α-SMA, PDGFRβ, and CD13.
  • Lower BMC marker levels correlated with poorer cognitive performance across multiple domains.
  • BMC marker reductions were associated with increased vascular Aβ40 and altered TDP-43 phosphorylation states, indicating BMC loss in AD.

Conclusions:

  • This study demonstrates a significant loss of BMCs in Alzheimer's Disease.
  • The findings link BMC loss to cognitive decline, TDP-43 aggregation, and cerebrovascular amyloid accumulation.
  • These results reinforce the connection between cerebrovascular dysfunction and dementia progression.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
459
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
707